GRAIL, Inc. $GRAL Shares Acquired by BlackRock Inc.

BlackRock Inc. grew its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 20.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,577,075 shares of the company’s stock after purchasing an additional 608,539 shares during the quarter. BlackRock Inc. owned 0.08% of GRAIL worth $244,207,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Fifth Third Bancorp increased its stake in GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares during the period. Comerica Bank lifted its holdings in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in GRAIL in the 4th quarter valued at approximately $28,000. Geneos Wealth Management Inc. boosted its position in GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after buying an additional 360 shares during the period. Finally, Elyxium Wealth LLC acquired a new position in shares of GRAIL in the fourth quarter worth $31,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wolfe Research started coverage on GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Robert W. Baird set a $70.00 target price on GRAIL in a research note on Wednesday, May 6th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group began coverage on GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $67.78.

Insider Transactions at GRAIL

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.83% of the stock is owned by company insiders.

GRAIL Trading Down 3.6%

Shares of GRAL opened at $79.59 on Thursday. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of -8.16 and a beta of 3.24. The firm’s fifty day simple moving average is $70.23 and its 200-day simple moving average is $63.65. GRAIL, Inc. has a twelve month low of $30.82 and a twelve month high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, analysts predict that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.